CancerCATANCT07107607
Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)
An observational study of Cancer and Cancer (With or Without Metastasis), run by HealthPartners Institute at 1 site in United States.
Trial summary
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Cancer, Cancer (With or Without Metastasis)
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 19 Mar 2021to Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: people with cancer who report that cannabis use had an impact on their cancer growth
Who may be able to join
- diagnosed with cancer
- have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
- believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Who cannot join
- does not have cancer
- has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
- does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Trial locations and contacts
1 site in 1 country.
United States1 site
HealthPartners Institute Cancer Research Center
Saint Louis Park, Minnesota, 55426
About this study
Official title: Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Read the detailed description
The purpose of the study is to further assess how cannabis may help control cancer growth and attempt to validate such claims. To do this, the investigators will review medical records from consented patients who report that cannabis has helped to reduce or control growth of cancer by assessing prior cancer treatments and assessments (for example, cancer/tumor labs like prostate-specific antigen (PSA), cancer antigen (CA)-125, carcinoembryonic antigen (CEA) and radiology imaging reports such as computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and magnetic resonance imaging (MRI)) as well as cannabis use details.
- Conditions
- Cancer, Cancer (With or Without Metastasis)
- Keywords
- cancer, cannabis, marijuana, tetrahydrocannabinol, cannabidiol
- Medical subject headings
- Neoplasms, Marijuana Abuse
What is being measured
The primary outcome is the main question the study is designed to answer.
To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.
Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.
Measured: From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2025
- Study start19 Mar 2021
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HealthPartners Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07107607
- Sponsor's protocol ID
- CATA
- Acronym
- CATA
- Status last verified
- May 2026
- First submitted
- 25 Jul 2025
- Last updated
- 7 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cannabis as an Anti-cancer Agent: A Review of Medical Records in Patients With Cancer to Assess Potential Anti-cancer Benefits From Using Cannabis
- ClinicalTrials.gov ID
- NCT07107607
- Acronym / sponsor ID
- CATA / CATA
- Conditions
- Cancer, Cancer (With or Without Metastasis)
- Keywords
- cancer, cannabis, marijuana, tetrahydrocannabinol, cannabidiol
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- HealthPartners InstituteUniversity, hospital or other
- Study start
- 19 Mar 2021 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 6 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to find out how cannabis may help control cancer growth by reviewing medical records of patients who report cannabis helped treat their cancer.
Detailed description
The purpose of the study is to further assess how cannabis may help control cancer growth and attempt to validate such claims. To do this, the investigators will review medical records from consented patients who report that cannabis has helped to reduce or control growth of cancer by assessing prior cancer treatments and assessments (for example, cancer/tumor labs like prostate-specific antigen (PSA), cancer antigen (CA)-125, carcinoembryonic antigen (CEA) and radiology imaging reports such as computed tomography (CT) scan, positron emission tomography (PET)/CT scan, and magnetic resonance imaging (MRI)) as well as cannabis use details.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- people with cancer who report that cannabis use had an impact on their cancer growth
Key inclusion criteria (3 listed)
- diagnosed with cancer
- have used any type of cannabis/marijuana, including those with cannabidiol (CBD) and/or tetrahydrocannabinol (THC) to treat their cancer
- believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Key exclusion criteria (3 listed)
- does not have cancer
- has not used any type of cannabis/marijuana, including those with CBD and/or THC to treat their cancer
- does not believe that cannabis has either stopped the tumor from growing and/or caused a cancer antigen blood marker to remain stable or cannabis has shrunken the tumor and/or caused reduction in a cancer antigen blood marker
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey.
Time frame: From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.
Successful completion of phase 2 of this survey study will include consenting 50 patients and obtaining their cancer and cannabis use details to validate anti-cancer claims.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Cancer (With or Without Metastasis), run by HealthPartners Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To successfully complete Phase 2 by recruiting patients to consent with a simplified screening survey. (time frame: From enrollment start to the obtainment of cancer diagnosis and treatment details and cannabis use history from each consented patient, which is estimated to take up to 6 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.